These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9869797)

  • 21. Examining the use of allopurinol: Perspectives from recent drug injury relief applications.
    Huang CH; Chu MP; Chen WW
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):371-377. PubMed ID: 29941331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of allopurinol in chronic kidney disease.
    Thurston MM; Phillips BB; Bourg CA
    Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
    Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein AC; Gunter MJ; Lafata JE; Harrold L; Nelson WW; Platt R
    Ann Pharmacother; 2006 Mar; 40(3):386-91. PubMed ID: 16478808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful desensitisation of allopurinol-induced erythema multiforme.
    Fonseka MM; Sathischandra H; Jayamanne SF; de Silva HJ
    Ceylon Med J; 1999 Dec; 44(4):190-1. PubMed ID: 10895280
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity.
    Gillott TJ; Whallett A; Zaphiropoulos G
    Rheumatology (Oxford); 1999 Jan; 38(1):85-6. PubMed ID: 10334688
    [No Abstract]   [Full Text] [Related]  

  • 27. Allopurinol induced generalized eosinophilic pustular folliculitis.
    Ooi CG; Walker P; Sidhu SK; Gordon LA; Marshman G
    Australas J Dermatol; 2006 Nov; 47(4):270-3. PubMed ID: 17034470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspirin use and risk of cataract in posttrial follow-up of Physicians' Health Study I.
    Christen WG; Ajani UA; Schaumberg DA; Glynn RJ; Manson JE; Hennekens CH
    Arch Ophthalmol; 2001 Mar; 119(3):405-12. PubMed ID: 11231774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do inhaled corticosteroids significantly increase cataract surgery in elderly patients?
    Franfelder FT
    Arch Ophthalmol; 1998 Oct; 116(10):1369. PubMed ID: 9790640
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolic syndrome, its components and risk of age-related cataract extraction: a case-control study in Italy.
    Galeone C; Petracci E; Pelucchi C; Zucchetto A; La Vecchia C; Tavani A
    Ann Epidemiol; 2010 May; 20(5):380-4. PubMed ID: 20382339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
    Yang CY; Chen CH; Deng ST; Huang CS; Lin YJ; Chen YJ; Wu CY; Hung SI; Chung WH
    JAMA Intern Med; 2015 Sep; 175(9):1550-7. PubMed ID: 26193384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How to prevent allopurinol hypersensitivity reactions?
    Stamp LK; Barclay ML
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i35-i41. PubMed ID: 29272508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study.
    Lin HC; Daimon M; Wang CH; Ho Y; Uang YS; Chiang SJ; Wang LH
    Int J Cardiol; 2017 Apr; 233():85-90. PubMed ID: 28202260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment failure gout: failure to treat?
    Perry ME; Madhok R
    Rheumatology (Oxford); 2010 Dec; 49(12):2233-4. PubMed ID: 20463191
    [No Abstract]   [Full Text] [Related]  

  • 35. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
    Jansen TLTA; Janssen M
    Clin Rheumatol; 2019 Jan; 38(1):263-265. PubMed ID: 30542798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis.
    Singh JA; Cleveland JD
    Arthritis Res Ther; 2018 Aug; 20(1):167. PubMed ID: 30075731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S; Liu X; Ming J; Chen S; Wang Y; Liu X; Liu H; Peng Y; Wang J; Lin J; Ji H; Liu B; Lu Y; Liu P; Zhang Y; Ji Q
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids.
    Garbe E; LeLorier J; Boivin JF; Suissa S
    Lancet; 1997 Oct; 350(9083):979-82. PubMed ID: 9329512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bullous cutaneous reactions.
    Jira M; Amezyane T
    Pan Afr Med J; 2018; 31():188. PubMed ID: 31065326
    [No Abstract]   [Full Text] [Related]  

  • 40. Preeclampsia and the risk of cataract extraction in life.
    Auger N; Rhéaume MA; Paradis G; Healy-Profitós J; Hsieh A; Fraser WD
    Am J Obstet Gynecol; 2017 Apr; 216(4):417.e1-417.e8. PubMed ID: 27899314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.